Showing results (321-330 of 378) with videos related to
Sort By:
Pageof 38
Seminars in Oncology|August 1, 1997
Docetaxel (Taxotere) and gemcitabine in the treatment of non-small cell lung cancer: preliminary resultsV Georgoulias, C Kourousis, N Androulakis, et al.Bone Marrow Transplantation|August 15, 2017
Low circulating mannan-binding lectin levels correlate with increased frequency and severity of febrile episodes in myeloma patients who undergo ASCT and do not receive antibiotic prophylaxisE Eleutherakis-Papaiakovou, M-A Dimopoulos, E Kastritis, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 19, 2007
VAD-doxil versus VAD-doxil plus thalidomide as initial treatment for multiple myeloma: results of a multicenter randomized trial of the Greek Myeloma Study GroupK Zervas, D Mihou, E Katodritou, et al.Bone Marrow Transplantation|July 31, 2001
Thiotepa, busulfan, cyclophosphamide (TBC) and autologous hematopoietic transplantation: an intensive regimen for the treatment of multiple myelomaA Shimoni, T L Smith, A Aleman, et al.Gynecologic Oncology|November 27, 2007
Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapyAristotelis Bamias, Vasiliki Koutsoukou, Evangelos Terpos, et al.Leukemia|July 24, 2009
Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myelomaM A Dimopoulos, C Chen, A Spencer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1997
Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescueS Giralt, D Weber, M Colome, et al.British Journal of Cancer|November 22, 2012
VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2N G Gavalas, M Tsiatas, O Tsitsilonis, et al.Acta Haematologica|April 2, 2005
Non-Hodgkin's lymphomas in Greece according to the WHO classification of lymphoid neoplasms. A retrospective analysis of 810 casesT Economopoulos, S Papageorgiou, M A Dimopoulos, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 10, 2011
The International Scoring System (ISS) for multiple myeloma remains a robust prognostic tool independently of patients' renal functionM A Dimopoulos, E Kastritis, E Michalis, et al.Pageof 38